ABT240927P114000
- 1.41
- +0.37+35.58%
Abbott Laboratories Newsroom
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Abbott Laboratories Analyst Ratings
Piper Sandler Initiates Abbott Laboratories(ABT.US) With Buy Rating, Announces Target Price $131
Buy Rating on Abbott Laboratories: Undervalued With Strong Growth Prospects Despite NEC Litigation
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Hold Rating on Abbott Laboratories Amid Lingo's Launch: Balancing Positive User Experience With Market Challenges
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Abbott Laboratories (ABT) Gets a Buy From Wells Fargo
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Hold Rating on Abbott Laboratories Amid NEC Litigation Uncertainties
Jefferies Maintains Abbott Laboratories(ABT.US) With Hold Rating, Raises Target Price to $120
BTIG Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $135
Abbott Laboratories Analyst Ratings
Citi Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $127
Medtronic Upgraded at UBS on Diabetes Turnaround
Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $143